ROYALTY PHARMA PLC- CL A
RPRXNASDAQTrading Snapshot
- Day Range
- $57.67 – $58.65
- 52-Week Range
- $34.63 – $64.38
- Volume
- $3.86B
- Avg Volume
- $4.34B
- Shares Outstanding
- 575.8M
- Next Earnings
- Nov 15, 2026
Fundamentals Snapshot
- Annual Revenue
- $2.38B
- Last Q Revenue
- $674M
- P/E Ratio
- 41.2
- P/S Ratio
- 13.2x
- EPS (TTM)
- $1.46
- Dividend Yield
- 1.19%
- Dilution (1yr)
- −5.0%
Why Investors Own RPRX
- ✓High-growth profile — revenue up +27.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 78% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ROYALTY PHARMA PLC- CL A
RPRX
StockOtter · stockotter.spaceAbout ROYALTY PHARMA PLC- CL A
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Royalty Pharma (NASDAQ:RPRX) Stock: Insider Christopher Hite Sells 100,000 Shares
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) EVP Christopher Hite sold 100,000 shares of the stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total value o
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disc
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of you
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript